Source: International Congress 2014 – Novel epigenetic regulators for targeting via nanomedicine
Disease area: Airway diseases

Abstract

Background: Lung inflammation is a characteristic hallmark of COPD, asthma bronchiale (AB) and pulmonary sarcoidosis (S). Profiles of inflammatory molecules are regulated posttranscriptionally by microRNA (miRNA). There is little information on bronchoalveolar (BAL) miRNA expression in vivo and on possible differences between aforementioned diseases which differ in their pathobiology. Method: Relative expression of 5 candidate miRNAs (mir-452, mir-129-3p, mir-146a, mir-21, mir-31) in BAL cells from non-smokers with COPD (n=10), AB (n=13), S (n=42) and healthy control subjects (n=8) was determined by Real-Time PCR. Results: Comparing with controls, BAL expression of mir-452 (p_COPD=0.01, p_AB=0.01, p_S<0.001) and mir-129 (p_COPD=0.03, p_AB=0.01, p_S<0.001) were decreased in all 3 investigated diseases. Mir-146a (p_AB=0.04, p_S=0.002) and mir-21 (p_AB=0.01, p_S=0.001) were decreased in AB and S, while mir-31 alone was decreased only in sarcoid BAL (p=0.001). Other two miRNAs (mir-452, mir-129) were downregulated in S compared to AB and COPD (p=0.001).



Conclusion: The differences in BAL miRNA expression between the investigated pulmonary diseases may contribute to variation of inflammatory response in their pathomechanisms. Characterisation of typical miRNA expression profiles is the next step of this work.Grant support IGAPULF2014_012, IGAMZ11117, CZ.1.05./2.1.00/01.0030.

Rating:

Share or cite this content

Citations should be made in the following way:
Z. Navratilova, E. Novosadová, T. Krsjakova, V. Kolek, M. Petrek (Olomouc, Czech Republic). Differential bronchoalveolar expression of candidate microRNAs in chronic obstructive pulmonary disease, asthma bronchiale and pulmonary sarcoidosis. Eur Respir J 2014; 44: Suppl. 58, 198

Member's Comments

No comment yet.

Related content which might interest you: The role of circulating mitochondrial DNA in modulating airway inflammation of chronic obstructive pulmonary disease Source: International Congress 2014 – Cell biology 2014 Year: 2014 Dynamics of sputum antimicrobial peptide levels in chronic obstructive pulmonary disease (COPD) Source: International Congress 2015 – Infection in COPD: different aspects of the host/pathogen balance Year: 2015 Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease Source: Annual Congress 2011 - Role of the biomarkers in airway diseases Year: 2011 Survivin in patients with chronic obstructive pulmonary disease Source: International Congress 2015 – Monitoring and phenotyping COPD Year: 2015 Common airway variants and chronic obstructive pulmonary disease Source: International Congress 2015 – New observations in respiratory epidemiology Year: 2015 Features of the bronchial mucosa in heavy smokers with and without chronic obstructive pulmonary disease Source: International Congress 2015 – COPD: interesting notes Year: 2015 Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease Source: Annual Congress 2013 –Investigating COPD in longitudinal studies Year: 2013 Comparison of inflammatory markers in induced and spontaneous sputum in COPD patients Source: International Congress 2014 – Translational studies in COPD Year: 2014 Multiple inflammatory hits and the pathogenesis of severe airway disease Source: Eur Respir J 2006; 27: 884-888 Year: 2006 Variability of bronchial inflammation in chronic obstructive pulmonary disease: implications for study design Source: Eur Respir J 2006; 27: 293-299 Year: 2006 Vascular endothelial dysfunction in chronic obstructive pulmonary disease: Comparison with bronchial asthma, and controls Source: International Congress 2016 – Systemic biomarkers Year: 2016 Dysregulation of serum miRNA in chronic obstructive pulmonary disease Source: International Congress 2015 – Genetics, genomics and exposures in asthma and COPD Year: 2015 Prognostic significance of neutrophil to lymphocyte ratio in chronic obstructive pulmonary disease Source: International Congress 2014 – Systemic and airway biomarkers Year: 2014 Definition and differential diagnosis of chronic obstructive pulmonary disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=1 Year: 2006 Biomarkers in the management of COPD Source: Eur Respir Rev 2009; 18: 96-104 Year: 2009 Evidence of mast-cell activation in a subset of patients with eosinophilic chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: 325-331 Year: 2002 Mucin 1 downregulation associates with corticoid resistance in chronic obstructive pulmonary disease and chronic rhinosinusitis with nasal polyps Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 Disturbed pulmonary immunity and the phenotype of alveolar macrophages in bronchial asthma, gastroesophageal reflux disease and their combination Source: International Congress 2014 – New insights into monocyte and macrophage biology Year: 2014 Inflammatory gene polymorphisms in asthma and chronic obstructive pulmonary disease in Venezuela Source: International Congress 2015 – Translational research in respiratory care: new findings Year: 2015 Recruitment of blood fibrocytes during acute exacerbations of chronic obstructive pulmonary disease through a CXCR4 dependent pathway Source: International Congress 2015 – The multiple facets of stem and progenitor cells in lung health and disease Year: 2015